Genelux Corp Stock Price, News & Analysis

Genelux (Nasdaq: GNLX) priced an underwritten public offering of 6,666,667 common shares at $3.00 per share, for gross proceeds of approximately $20.0 million before underwriting discounts, commissions and expenses. The company granted a 30-day option for the underwriter to buy up to an additional 1,000,000 shares at the public price less discounts. Net proceeds are expected to be used for general corporate purposes, including R&D, clinical trial expenses, capital expenditures and working capital. The offering is expected to close on or about January 9, 2026, subject to customary closing conditions.

Genelux (Nasdaq: GNLX) announced a proposed underwritten public offering of its common stock on January 7, 2026. The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares sold. All shares will be offered by Genelux and the offering is subject to market and customary closing conditions, so completion, size and terms are not assured. Lucid Capital Markets is the sole book-running manager. The offering will be made from an effective shelf registration filed February 2, 2024 and declared effective February 13, 2024, with a preliminary prospectus supplement to be filed with the SEC.

Genelux (NASDAQ: GNLX) reported interim systemic Olvi-Vec data from ongoing lung cancer trials as of December 2025. In Phase 1b/2 SCLC (9 evaluable patients) the overall response rate was 33% (3/9), with two partial responses in the highest tested dose cohort showing ~55% and ~85% tumor shrinkage; disease control rate was 67% (6/9). In Phase 2 VIRO-25 NSCLC (5 evaluable patients) disease control rate was 60% (3/5) with tumor changes of +8.9%, -18.9%, and -22.7%. Olvi-Vec was reported as generally well tolerated. Additional lung cancer readouts and Phase 3 ovarian topline data expected throughout 2026.

Genelux (NASDAQ: GNLX) appointed Jason Litten, M.D. as Chief Medical Officer, effective January 2, 2026.

Dr. Litten will oversee clinical development and medical strategy as Genelux advances Olvi-Vec toward upcoming pivotal readouts in ovarian and lung cancer. He brings over 20 years of oncology development experience across biologics, small molecules, and cell therapies, with prior CMO roles at Chimeric Therapeutics and Artiva and senior positions at Juno, Clovis, and Amgen. In connection with his hire, Genelux granted an inducement stock option for 275,000 shares under the 2023 Inducement Plan, exercisable at the closing price on the grant date and vesting over four years (25% at one year, then monthly over 36 months).

Genelux (NASDAQ: GNLX) announced that Thomas Zindrick, President, CEO and Chairman, and Matt Pulisic, CFO, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York.

A live webcast will be available during the event and an archived replay will be posted on the company's investor website at https://investors.genelux.com/.

Genelux (NASDAQ: GNLX) reported third quarter 2025 results and clinical updates on Nov 5, 2025. The company held $21.0 million in cash, cash equivalents, short-term investments and restricted cash as of Sept 30, 2025, which management expects will fund operations into the third quarter of 2026. Topline data from the OnPrime Phase 3 ovarian cancer registrational trial is now anticipated in the second half of 2026. Additional interim data from two systemically delivered Olvi-Vec lung cancer trials are expected in Q4 2025 and through 2026. Q3 2025 net loss was $8.0 million (loss per share $0.21); R&D was $4.7 million and G&A was $3.5 million.

Key program notes: OnPrime remains enrolling in the U.S.; the Independent Data Monitoring Committee has recommended continuation; company believes positive PFS without OS decrement could support traditional FDA approval based on a Type D meeting.

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright Global Investment Conference. CEO and Chairman Thomas Zindrick and CFO Matt Pulisic will engage in a fireside chat on September 9, 2025, at 2:30 p.m. ET, moderated by Biotech Equity Research Analyst Emily Bodnar.

The company will also conduct one-on-one meetings with institutional investors during the conference. A replay of the session will be available for approximately 90 days on Genelux's IR page.

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported Q2 2025 financial results and provided pipeline updates. The company's lead candidate Olvi-Vec is advancing in multiple clinical trials, with key data readouts expected. The Phase 3 OnPrime/GOG-3076 registrational trial in platinum-resistant/refractory ovarian cancer (PRROC) is progressing toward topline data in H1 2026.

Financial highlights include cash position of $28.1 million as of June 30, 2025, providing runway into Q3 2026. Q2 2025 resulted in a net loss of $7.5 million ($0.20 per share), compared to $6.6 million ($0.22 per share) in Q2 2024. The company strengthened its leadership team with Eric Groen joining as General Counsel and Head of Business Development.

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has appointed Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025.

Groen brings over 20 years of experience in the life sciences industry, notably serving at Rani Therapeutics and Amgen, where he played a key role in the $10 billion Onyx Pharmaceuticals acquisition. As part of his appointment, Groen received an inducement award of 270,000 stock options at $2.83 per share, vesting over four years.